Press Releases


Test Offers Significant Clinical Benefits

Copiague, New York, July 19, 2000 - American Biogenetic Sciences, Inc. (ABS) (Nasdaq: MABA - news) announced today that a clinical article recently published in the journal Blood Coagulation Fibrinolysis reported that in a comparison of coagulation markers, ABS's diagnostic Thrombus Precursor Protein (TpPTM) demonstrated 100% sensitivity and negative predictive value for evaluating proximal deep vein thrombosis (PDVT) and pulmonary embolism (PE).

The article "The use of thrombus precursor protein, D-dimer, prothrombin fragment F1.2 and thrombin antithrombin in the exclusion of proximal deep vein thrombosis and pulmonary embolism" Blood Coagulation Fibrinolysis 2000;11(4):371-377, contains data that indicate TpP offers significant clinical benefits.

"This data suggests that TpP may have potential in ruling out acute presentation of PDVT and PE, with the subsequent improvement in overall patient care due to a reduction in the need for invasive and costly diagnostic procedures as well as a reduction in the time spent in the hospital," said Yale S. Arkel, M.D., Director of Thrombosis Research Program, Maine Medical Center Research Institute, who is leading ABS's clinical development of TpP.

Commenting on this development, Mr. John S. North, President and CEO of ABS, said, "We welcome this recent publication to the growing body of clinical evidence that affirms the uniqueness and superiority of our TpP diagnostic test. It is clear to us that this test has great potential in the diagnosis and monitoring of thrombotic disease, the number one cause of mortality and morbidity in developed countries.

In the United States alone more than 55 million individuals currently suffer from conditions associated with thrombosis. Venous thrombosis and its complication pulmonary embolism are responsible for greater than 50,000 deaths annually and new cases are noted in greater than 300,000 patients each year. Both indications are a major cause of disability with a high incidence affecting younger patients and are often seen as a complication of pregnancy.

American Biogenetic Sciences, Inc. based in Copiague, N.Y., researches and develops diagnostics tests for cardio-pulmonary conditions and infectious diseases, as well as new treatments for neurological disorders including epilepsy, migraine, mania, Parkinson's disease and Alzheimer's disease. ABS also seeks out new technologies and conducts research and development through its Global Scientific Network in the United States, Europe, Israel, Russia and China.

Statements in this release that are not strictly historical are "forward looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, and should be considered as subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. For further details and a discussion of these risks and uncertainties, see the Companys' Securities and Exchange Commission filings including its annual report on Form 10-K.



American Biogenetic Sciences, Inc. 2000